Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs RLX Technology Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while RLX Technology Inc trades at $1.7 (market cap $2.09B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 4.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.85% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and RLX Technology Inc for 36 Days on average.
| KYMR | RLX | |
|---|---|---|
Market Cap | $8.88B | $2.09B |
Volume | 1,028,790 | 2,906,236 |
Sector | Health | Consumer Staples |
52-Week High | $127.31 | $2.57 |
52-Week Low | $55.80 | $1.68 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $8.27B | $817.70M |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RLX Technology trades at $1.71, down 0.58% and near its 52-week low of $1.67. The stock shows bearish technical signals with recent earnings misses in Q4 2025-Q2 2026. Fundamentally, the company maintains solid profitability with 21.87% net margin and trades at attractive valuations (P/E 15.34, P/B 0.9). International expansion drives revenue growth, with 70% of sales now from overseas markets following European acquisitions.
RLX presents a value opportunity with discounted valuation metrics, though near-term headwinds include earnings volatility and technical weakness. The international growth strategy provides upside potential, but regulatory risks in the e-vapor industry and recent margin compression require monitoring. With only one analyst coverage recommending Hold, investor sentiment remains cautious despite the stock's fundamental strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
